Top

Osteoporosis International

Published in:

01-05-2015 | Letter

Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers

Authors: E. B. Andrews, A. W. Gilsenan, K. D. Midkiff, D. H. Harris

Published in: Osteoporosis International | Issue 5/2015

Excerpt

Dear Editor, …

Bang UC, Hyldstrup L, Jensen JEB (2014) The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int 25:639–644. doi:10.1007/s00198-013-2470-y CrossRefPubMed

Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321CrossRefPubMed

NPS Pharma Holdings Limited (2014) Preotact parathyroid hormone (rDNA). Summary of product characteristics. .http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000659/human_med_000984.jsp&mid=WC0b01ac058001d124. Accessed 5 March 2014.

Eli Lilly Nederland B.V. (2013) Forsteo (teriparatide). Summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000425/human_med_000798.jsp&mid=WC0b01ac058001d124. Accessed 2 April 2014.

Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J editors (2013) Cancer incidence in five continents, vol. X (electronic version). Lyon, International Agency for Research on Cancer. http://ci5.iarc.fr. Accessed on 13 February 2014

Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res 27:2429–2437. doi:10.1002/jbmr.1768 CrossRefPubMedCentralPubMed

Sørensen HT, Christensen T, Schlosser HK, Pedersen L, editors (2009) Use of medical databases in clinical epidemiology, second edition. http://kea.au.dk/download/Use_of_medical_databases_in_clinical_epidemiology_2nd_ed_472.pdf. Accessed 2 April 2014

Title: Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers
Authors: E. B. Andrews
A. W. Gilsenan
K. D. Midkiff
D. H. Harris
Publication date: 01-05-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 5/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-3003-z

At a glance: The STEP trials

Springer Medicine

Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2015

Bisphosphonate therapy: how long is long enough?

Bone mineral density in patients with symptoms suggestive of spondyloarthritis

Sex-specific differences in progressive glucose intolerance and hip geometry: the Baltimore Longitudinal Study of Aging

Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis

Regional variability in changes in the incidence of hip fracture in the Spanish population (2000–2012)

Plasma dimethylglycine, nicotine exposure and risk of low bone mineral density and hip fracture: the Hordaland Health Study